NovaBiotics Logo

NovaBiotics Ltd
Cruickshank Building
Craibstone
Aberdeen
AB21 9TR
UK

Site Map
Novamycin®
Lynovex™
Novarifyn™
Pipeline
News and Press
Contract Research
Contact Us
© NovaBiotics Ltd 2011

 

 

 

What is a fungal nail infection?

What causes nail fungus?

How was Novexatin® discovered?

How will Novexatin®be used?

What does Novexatin®look like?

Does Novexatin®cause any side effects?

I am having limited success with nail fungus treatment currently available, why would I use Novexatin®?

When will Novexatin® be available?

Can I be involved in the further clinical trials for Novexatin®?

 

What is a fungal nail infection?

Please consult your GP or podiatrist/chiropodist for any diagnosis. Fungal nail infections (onychomycosis) account for over 50% of all clinical nail problems. The infections can lead to a number of changes in the appearance and condtion of the nail (generally toe nails, but also fingernails) including changes in shape and structure, discolouration, brittleness, spltting, thickening etc. The nail bed and/or the nail plate can be infected to various degrees and infections range from mild to severe but most commonly presents as mild-to-moderate infection of the toe nail plate. Toenails affected by onychomycosis can become so thick that routine trimming of the nail becomes difficult and wearing shoes causes pain making it difficult to walk, work and do other activities.

What causes nail fungus?

A group of Fungi known as dermatophytes are the primary cause of fungal nail infections (Onychomycosis). These microbes can grow on keratin (a major compent of nail, skin and hair). Fungal nail infections can involve the nail plate and/or the nail bed and, in some cases, the skin surrounding the nail plate.

How was Novexatin® discovered?

The naturally occuring antimicrobial peptides that the body produces in order to protect the skin and other organs against infection are the basis on which Novexatin® and NovaBiotics' other drugs have been engineered. In doing so we have capitalised on the beneficial microbial properties of these natural infection-fighting agents and have designed third generation peptide therapeutics such as Novexatin® that can be applied for the treatment and even prevention of a range of fungal and bacterial infections.

How will Novexatin® be used?

At the moment, as Novexatin® goes through its clinical studies, it is brushed on to the nail every day for one month. We anticipate that this is how the final product will be used.

What does Novexatin® look like?

Novexatin® is a clear/slightly opaque solution that dries to form an almost invisible colourless film on the nail when brushed on.

Does Novexatin® cause any side effects?

Novexatin® could not be detected in plasma from any patients up to 16 hours after exposure to the drug and no adverse reactions were reported during the first stage of the clinical trials.

I am having limited success with nail fungus treatment currently available, why would I use Novexatin®?

One of the most important features of Novexatin® is that in the tests we've carried out thus far it clears infection and works much faster than currently available treatments. Another important difference is that the active compound in Novexatin® kills the fungi that cause nail infections rather than merely inhibiting tehir growth, as most products do. This means relapse of infection within a full nail growth cycle is much less likely.

When will Novexatin® be available?

Novexatin® is now well on its way to being a drug but it will be at least 3 more years until it's an approved medicinal product that can be prescribed by your GP or specialist physician.

Can I be involved in the further clinical trials for Novexatin®?

This website will have details of any and all subsequent clinical trials that Novexatin® will have to go through and we definitely hope that a component of future clinical evaluation will take place locally, but this depends on the design, structure and size of such studies

 

Home
NovaBiotics®
Novexatin®
Technology Summary
In vitro and ex vivo activity
Clinical Evaluation
FAQs
Press Releases